Advertisement

Topics

Gilead and Insitro Collaborate for Discovery and Development of Novel Therapies for Nonalcoholic Steatohepatitis

12:07 EDT 16 Apr 2019 | Speciality Pharma Journal

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Gilead Sciences Inc. (Nasdaq: GILD) and insitro announced today that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH). Under the terms of the three-year collaboration, insitro’s proprietary platform will be utilized to create disease models for …

Original Article: Gilead and Insitro Collaborate for Discovery and Development of Novel Therapies for Nonalcoholic Steatohepatitis

NEXT ARTICLE

More From BioPortfolio on "Gilead and Insitro Collaborate for Discovery and Development of Novel Therapies for Nonalcoholic Steatohepatitis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...